<DOC>
	<DOCNO>NCT02510300</DOCNO>
	<brief_summary>This Registry enroll adolescent pediatric participant receive least one Gilead Hepatitis C Virus ( HCV ) direct act antiviral ( DAA ) participate Gilead-sponsored chronic hepatitis C clinical trial . The primary objective Registry determine long-term safety anti-HCV regimen pediatric population . Secondary objective Registry determine whether subsequent detection HCV RNA participant relapse follow sustain virologic response ( SVR ) represent re-emergence pre-existing virus , development resistance mutation , whether due re-infection , characterize resistance mutation persistence resistance mutation pediatric participant achieve SVR . Once enrol , participant follow 5 year .</brief_summary>
	<brief_title>A Registry Adolescent Pediatric Participants Who Received Gilead Hepatitis C Virus Direct Acting Antiviral ( DAA ) Gilead-Sponsored Chronic Hepatitis C Infection Trials</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Have previously participate Gileadsponsored chronic hepatitis C study adolescent pediatric participant receive least one Gilead HCV direct act antiviral Parent legal guardian able provide write informed consent OR individual able provide write informed consent prior study procedure willing comply study requirement determine institutional review board ( IRB ) /independent ethic committee ( IEC ) /local requirement Investigator 's discretion . Individual able provide write assent , ability read write , determine IRB/IEC/local requirement Investigator 's discretion Individual currently receive plan initiate new course hepatitis C therapy include investigational drug device course followup Registry . History clinicallysignificant illness major medical disorder may interfere individual 's followup , assessment compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>